Clinical Trials

19 enrolled

Phase 2 Not yet recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT07460245 2026-03-10

AVESEC

144 enrolled

Carcinoma, Transitional Cell

NCT03719768 2026-03-02

Avelumab With Radiotherapy in Patients With Leptomeningeal Disease

16 enrolled

CNS

Brain Neoplasms, Meningeal Neoplasms, Meningeal Carcinomatosis

NCT03006848 2026-02-23

A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma

19 enrolled 11 charts

Sarcoma

Osteosarcoma

NCT03252938 2026-02-19

INSIGHT

Phase EARLY_PHASE1 Active not recruiting

83 enrolled

GenitourinaryGynecologic

Carcinoma, Transitional Cell, Peritoneal Neoplasms

NCT05358938 2026-02-06

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

22 enrolled

Melanoma, Motor Activity, Skin Neoplasms, Carcinoma, Merkel Cell

NCT03944941 2026-02-05

Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer

60 enrolled

Skin Neoplasms

NCT04701918 2026-01-22

Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma

9 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04360941 2026-01-21

PAveMenT

Phase 1 Recruiting

45 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02813135 2026-01-16

ESMART

472 enrolled

Neoplasms

NCT05327686 2026-01-14

SAMURAI

240 enrolled

Carcinoma, Renal Cell

NCT07110038 2026-01-12

DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma

25 enrolled

Penile Squamous Cell Carcinoma (PSCC)

NCT06518564 2026-01-07

Avelumab and M1774 in ARID1A-mutated Endometrial Cancer

25 enrolled

Gynecologic

Endometrial Neoplasms

NCT03391479 2025-12-18

A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy

25 enrolled

Neoplasm Metastasis, Penile Neoplasms

NCT03575013 2025-12-03

A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer

21 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Transitional Cell

NCT04266912 2025-11-25

Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

23 enrolled 11 charts

Neoplasm Metastasis

NCT03747419 2025-10-31

Avelumab and Radiation in Muscle-Invasive Bladder Cancer

Phase 2 Terminated

14 enrolled 14 charts

Phase 1/2 Active not recruiting

Urinary Bladder Neoplasms

NCT03217747 2025-10-23

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

173 enrolled 28 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

126 enrolled

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT03147287 2025-09-30

Palbociclib After CDK and Endocrine Therapy (PACE)

220 enrolled 11 charts

Breast Neoplasms

NCT04678362 2025-09-22

TALASUR

50 enrolled

Phase 3 Active not recruiting

Carcinoma, Transitional Cell

NCT03271372 2025-09-17

ADAM

101 enrolled

Carcinoma, Merkel Cell

NCT04258956 2025-09-11

AXAGIST

58 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT04387084 2025-09-05

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

10 enrolled

Skin Neoplasms

NCT04242238 2025-08-28

Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas

32 enrolled

Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT04792073 2025-08-11

Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma

18 enrolled

Neoplasm Metastasis, Carcinoma, Merkel Cell

NCT04341181 2025-07-25

ProTarget

300 enrolled

Neoplasms

NCT02912572 2025-07-10

Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

106 enrolled 16 charts

Gynecologic

Endometrial Neoplasms

NCT03414658 2025-07-02

The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

100 enrolled 15 charts

Breast Neoplasms

NCT03186326 2025-06-29

SAMCO

132 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT03357757 2025-06-26

LATENT

Phase 1/2 Active not recruiting

39 enrolled

GastrointestinalLymphoid

Cancer That is Associated With a Chronic Viral Infection

NCT03826589 2025-06-11

ALARICE

Phase NA Completed

23 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT03964532 2025-05-21

TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer

24 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT02999087 2025-05-07

REACH

707 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03971409 2025-05-02

InCITe

150 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05217069 2025-04-16

FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC

57 enrolled

Neoplasms, Second Primary

NCT03498378 2025-04-03

Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

24 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasms

NCT04291885 2025-04-03

I-MAT

122 enrolled

DermatologicEndocrineNET

Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT06892860 2025-03-25

DISCUS

320 enrolled

Urinary Bladder Neoplasms

NCT03893903 2025-03-14

AMPLIFY-NEOVAC

69 enrolled

CNS

Glioma

NCT06869473 2025-03-14

AVEC-119

67 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT04841148 2025-03-11

PALAVY

96 enrolled

Breast Neoplasms, Neoplasm, Residual

NCT03747484 2025-03-06

Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

Phase 1/2 Terminated

7 enrolled 15 charts

Neoplasm Metastasis, Carcinoma, Merkel Cell

NCT03674424 2025-02-26

AURA

137 enrolled

Non-metastatic Muscle Invasive Bladder Cancer

NCT04322643 2025-02-25

Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma

Phase 2 Terminated

4 enrolled 10 charts

Carcinoma, Transitional Cell

NCT04261855 2025-02-14

GoTHAM

19 enrolled

DermatologicEndocrineNET

Carcinoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT03636503 2025-02-06

Rituximab + Immunotherapy in Follicular Lymphoma

Phase 1 Terminated

24 enrolled 25 charts

Lymphoid

Lymphoma, Lymphoma, Follicular

NCT03707808 2025-01-20

myDAvIpNi

Phase 3 Active not recruiting

18 enrolled

Other solid neoplasm

Solid Tumor

NCT04637594 2025-01-15

IMAGINE

3 enrolled